American College of Gastroenterology (ACG 2021) Annual Scientific Meeting

Virtual 22 October 2021 - 27 October 2021

Dupilumab benefits in EoE sustained through 52 weeks

23 Nov 2021 by

The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.

Dupilumab benefits in EoE sustained through 52 weeks

23 Nov 2021

Vonoprazan trumps PPI in ridding off H. pylori

18 Nov 2021 by

Vonoprazan-containing triple- or dual-therapy regimens are superior to lansoprazole triple therapy in eradicating Helicobacter pylori (H. pylori), according to the phase III pHalcon-HP study presented at ACG 2021.

Vonoprazan trumps PPI in ridding off H. pylori

18 Nov 2021

Double trouble: Alcohol-related liver diseases take a turn for the worse during COVID-19

15 Nov 2021 by

Higher intake of alcohol and reduced care during the COVID-19 pandemic have triggered a spike in alcohol-related liver diseases, leading to some serious consequences, according to new research.

Double trouble: Alcohol-related liver diseases take a turn for the worse during COVID-19

15 Nov 2021

Upadacitinib scores big in UC

14 Nov 2021 by

The oral Janus kinase 1 (JAK1) inhibitor upadacitinib scores big in ulcerative colitis (UC), with promising results from U-ACCOMPLISH, one of two phase III trials completed for the drug.

Upadacitinib scores big in UC

14 Nov 2021